A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/08/2011	US8053426 Progesterone receptor antagonists
11/08/2011	US8053425 Such as skin grafts; decubitus ulcer
11/08/2011	US8053424 Composition and method of treating hearing loss
11/08/2011	US8053422 Anti-cancer oligodeoxynucleotides
11/08/2011	US8053420 Enhance cellular uptake of uncharged antisense oligonucleotide; forming a conjugate and arginine-rich peptide; oligonucleotide includes a string of contiguous guanine bases; substitute inosine base to limit the number of contiguous guanine bases to three; cancer, polycystic kidney disease, restenosis
11/08/2011	US8053419 Synthetic genes and genetic constructs
11/08/2011	US8053418 Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative
11/08/2011	US8053417 Mucosal adjuvants elicit strong balanced or adjusted immune response of humoral, cellular components; prophylaxis or treatment of infectious diseases or cancer; non-toxic; employed with a wide variety of active ingredients to be assisted in conventional or novel vaccines
11/08/2011	US8053416 Isolation and structure of turbostatins 1-4
11/08/2011	US8053413 Ameliorating breathing disorder using cholecystokinin (CCK) receptor antagonist
11/08/2011	US8053206 Antagonists of HMG1 for treating inflammatory conditions
11/08/2011	US8053000 Compositions for drug delivery
11/08/2011	US8052998 Mixture of biodegradable polymer and cationic polymer
11/08/2011	US8052995 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
11/08/2011	US8052994 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
11/08/2011	US8052993 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
11/08/2011	US8052992 Lipid preparation including glycerophospholid esters with polyunsaturated fatty acid (PUFA); increased bioavailability of PUFA; use as pharmaceutical, nutraceutical e.g. neurodegenerative disorders
11/08/2011	US8052987 Intermittently administering a bisphosphonate to patient, wherein period between administrations of bisphosphonate is at least 6 months; treatment of osteoporosis
11/08/2011	US8052984 Increased effectiveness of allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages
11/08/2011	US8052983 Administering a photosensitive, non-antibiotic tetracycline, preferably chosen from CMT-1 through CMT-10, without administering a bisphosphonate compound; side effect reduction
11/08/2011	US8052975 Compounds and methods for treatment and diagnosis of chlamydial infection
11/08/2011	US8052972 Remedies for inflammatory bowel diseases
11/08/2011	US8052966 gene therapy; producing targeted viral and non-viral particles delivery vectors for treating neoplastic disorders; retroviral, adenoviral, adeno-associated virus, Herpes Virus, and pseudotyped viruses, vesicular stomatitis virus G-protein (VSV-G), and to non-viral vectors that contain a viral protein
11/08/2011	US8052963 [(4-oxo-4H-chromen-3-yl)hydroxymethyl]- or [(4-oxo-4H-chromen-3-yl)methyl]phosphonic acid derivatives
11/08/2011	CA2665048C Crystalline forms of thiazolidinedione compound and its manufacturing method
11/08/2011	CA2643300C Trans-fused chromenoisoquinolines, synthesis and methods for use
11/08/2011	CA2631233C Ganaxolone formulations and methods for the making and use thereof
11/08/2011	CA2630262C The use of isothiocyanates compounds in treating prostatic diseases and skin cancer
11/08/2011	CA2618393C Bis-aryl amide compounds and methods of use
11/08/2011	CA2605222C Methods and compositions for the prevention and treatment of kidney disease
11/08/2011	CA2601132C Use of n-methylglycine and pharmaceutical compositions comprising n-methylglycine for treating neuropsychiatric disorders
11/08/2011	CA2598595C Cycloalkylcarboxyl derivatives that stimulate glucose utilization and method of use
11/08/2011	CA2596752C Derivatives of 4-demethylpenclomedine, use thereof and preparation thereof
11/08/2011	CA2569674C Sublingual buccal effervescent
11/08/2011	CA2545086C Vaccine composition admixed with an alkylphosphatidylcholine
11/08/2011	CA2535637C Quinolone antibiotics for the systemic treatment of bacterial infections of the oral cavity
11/08/2011	CA2529126C Azetidine compounds
11/08/2011	CA2528312C Methods of managing the symptoms of premenstrual syndrome
11/08/2011	CA2526594C Use of tyrosine kinase inhibitors to treat diabetes
11/08/2011	CA2526208C Infusion preparation for peripheral parenteral administration and method for stabilizing vitamin b1
11/08/2011	CA2524069C Substituted dihydroquinazolines
11/08/2011	CA2522738C Compounds for the treatment of metabolic disorders
11/08/2011	CA2522292C Nasal pharmaceutical formulations and methods of using the same
11/08/2011	CA2516263C Benzofuranoxyethylamines as antidepressants and anxiolytics
11/08/2011	CA2513522C Skin composition
11/08/2011	CA2512015C Topical stabilized prostaglandin e compound dosage forms
11/08/2011	CA2509982C N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
11/08/2011	CA2509072C Saturated and unsaturated heteroarylcycloalkylmethyl-amines as antidepressants
11/08/2011	CA2507595C Use of dextran sulfate in the treatment of instant blood-mediated inflammatory reaction
11/08/2011	CA2507131C .beta.-1,4-mannobiose-containing composition
11/08/2011	CA2499639C Imidazopyridines as cyclin dependent kinase inhibitors
11/08/2011	CA2498945C Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiazoles from cyclohexanes and cyclohexanones as intermediates
11/08/2011	CA2493690C Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
11/08/2011	CA2493436C Indolinone derivatives, substituted in the 6-position, their preparation and their use as medicaments
11/08/2011	CA2476430C Sodium channel blockers
11/08/2011	CA2476054C Pharmaceutical composition for the oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino)-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino)-propionic acid ethyl ester and the salts thereof
11/08/2011	CA2466321C Gel comprising at least a retinoid and benzoyl peroxide
11/08/2011	CA2460572C Dual action antibiotics
11/08/2011	CA2451552C Topical application of thiazolylamides
11/08/2011	CA2443105C Functional role for cannabinoids in autonomic stability during sleep
11/08/2011	CA2442539C Method and composition for solubilising a biologically active compound with low water solubility
11/08/2011	CA2432185C Substituted pyridoindoles as serotonin agonists and antagonists
11/08/2011	CA2431675C Novel sulfamides and their use as endothelin receptor antagonists
11/08/2011	CA2405408C Pyrazole compounds
11/08/2011	CA2343414C Fc receptor modulators and uses thereof
11/08/2011	CA2302754C Noribogaine in the treatment of pain and drug addiction
11/08/2011	CA2249596C Methods for enhancing functional recovery following central nervous system ischemia or trauma
11/08/2011	CA2247285C Human tumor necrosis factor delta and epsilon
11/05/2011	CA2817112A1 Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
11/05/2011	CA2707280A1 Stabilized synthetic brood pheromone and race-specific ratios of components for manipulating the behavior and physiology of honey bees
11/04/2011	CA2758029A1 Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
11/03/2011	WO2011137459A1 Dosage forms of elinogrel and methods of injectable administration thereof
11/03/2011	WO2011137456A2 Methods and mechanisms involving hyperpigmentation particularly for african american skin
11/03/2011	WO2011137447A1 Antiviral compounds
11/03/2011	WO2011137428A1 Methods of treating hiv infection: inhibition of dna dependent protein kinase
11/03/2011	WO2011137427A2 Compositions and methods for treating pulmonary conditions
11/03/2011	WO2011137390A1 Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies
11/03/2011	WO2011137376A2 Compounds for anti-fungal treatment
11/03/2011	WO2011137363A1 Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
11/03/2011	WO2011137342A1 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites
11/03/2011	WO2011137331A2 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
11/03/2011	WO2011137321A1 Thickened compositons of high ph
11/03/2011	WO2011137320A2 Small molecule inhibitors of usp1 deubiquitinating enzyme activity
11/03/2011	WO2011137313A1 Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs
11/03/2011	WO2011137274A1 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
11/03/2011	WO2011137249A1 Prebiotic formulations and methods of use
11/03/2011	WO2011137219A1 Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
11/03/2011	WO2011137181A1 Synthetic oligosaccharides for moraxella vaccine
11/03/2011	WO2011137173A1 Method and medication for prevention and treatment of ocular hypertension and glaucoma
11/03/2011	WO2011137155A1 Imidazopyridazinyl compounds and their uses for cancer
11/03/2011	WO2011137135A1 Chemical compounds
11/03/2011	WO2011137126A1 Formulations of quinones for the treatment of ophthalmic diseases
11/03/2011	WO2011137109A1 Azaindazole amide compounds as ccr1 receptor antagonists
11/03/2011	WO2011137089A1 Activators of human pyruvate kinase
11/03/2011	WO2011137054A1 Novel beta 3 adrenergic receptor agonists
11/03/2011	WO2011137049A1 Heterocyclic quinolizine derived m1 receptor positive allosteric modulators
11/03/2011	WO2011137046A1 Substituted 1,3-benzothiazol-2(3h)-ones and [1,3]thiazolo[5,4-b]pyridin-2(1h)-ones as positive allosteric modulators of mglur2
11/03/2011	WO2011137022A1 Azaindoles as janus kinase inhibitors
11/03/2011	WO2011137012A1 Prolylcarboxypeptidase inhibitors
11/03/2011	WO2011137002A1 N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives

1 ... 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 ... 7860